久久无码人妻一区二区三区午夜_久久久久精品久久久久影院蜜桃_亚洲综合欧美色五月俺也去_交换娇妻呻吟声不停中文字幕

南京科佰生物科技有限公司

當(dāng)前位置:南京科佰生物科技有限公司>>藥靶細(xì)胞株>>kinase激酶細(xì)胞株>> CBP73192SLC34A2-ROS1 G2032R/BaF3

SLC34A2-ROS1 G2032R/BaF3

參  考  價(jià):面議
具體成交價(jià)以合同協(xié)議為準(zhǔn)

產(chǎn)品型號(hào)CBP73192

品牌cobioer/科佰生物

廠商性質(zhì)代理商

所在地南京市

更新時(shí)間:2022-05-05 16:49:34瀏覽次數(shù):762次

聯(lián)系我時(shí),請告知來自 化工儀器網(wǎng)
供貨周期 現(xiàn)貨 規(guī)格 T-25 Flask
貨號(hào) CBP73192 應(yīng)用領(lǐng)域 生物產(chǎn)業(yè)
主要用途 僅限科研使用
SLC34A2-ROS1 [G2032R]/BaF3,母細(xì)胞:BaF3,凍存條件:90% FBS+10% DMSO
CBP73192
I. Introduction

Cell Line Name:

SLC34A2-ROS1 [G2032R]/BaF3

Host Cell:

Ba/F3

Stability:16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10%FBS

Mycoplasma Status:

Negative


II.Background

Approximately 2% of lung tumors harbor ROS1 fusions (Bergethon et al. 2012). Like ALK fusions, ROS1 fusions are more commonly found in light smokers (<10 pack years) and/or never-smokers. ROS1 fusions are also associated with younger age and adenocarcinomas (Bergethon et al. 2012).

In preclinical models, ROS1 fusions are associated with sensitivity to tyrosine kinase inhibitors that have 'off-target' activity against ROS1, such as crizotinib (Bergethon et al. 2012; Davies et al. 2012). In addition, two patients—a previously treated metastatic NSCLC patient and a 65-year-old never smoker NSCLC patient—with tumors harboring ROS1 fusions have had partial responses to crizotinib (Bergethon et al. 2012; Davies et al. 2012). In an expansion cohort of a phase I study, 50 patients with ROS1-positive NSCLC demonstrated a 72% response rate and 19.2-month median progression-free survival interval when treated with crizotinib (Ou et al. 2013; Shaw et al. 2014). In a European case study, 32 ROS1-positive NSCLC cases treated with crizotinib were retrospectively reviewed, and an 80% response rate and a 9.1-month median progression-free survival interval was calculated in this cohort (Mazières et al. 2015).

Several different ROS1 rearrangements have been described in NSCLC. These include SLC34A2-ROS1, CD74-ROS1, EZR-ROS1, TPM3-ROS1, and SDC4-ROS1 (Figure 1; Davies et al. 2012; Rikova et al. 2007; Takeuchi et al. 2012). Clinically, the presence of a ROS1 rearrangement is detected by fluorescence in situ hybridization (FISH) with a ROS1 breakapart probe. FISH testing is not able to discern which particular ROS1 fusion is found in a clinical sample.

ROS1 rearrangements are non-overlapping with other oncogenic mutations found in NSCLC (e.g., EGFR mutations, KRAS mutations, ALK fusions, etc.; Bergethon et al. 2012).


III. Representative Data

1. WB of SLC34A2-ROS1 [G2032R]/BaF3expression

CBP73192 WB.png


Figure 1. Protein Expression of ROS1 detected by antibody


2.Sanger Sequencing of SLC34A2-ROS1 Fusion and G2032R mutation

CBP73192 sanger-1.png

Figure 2. SLC34A2-ROS1 Fusion

CBP73192 sanger2.png

Figure 3. ROS1 p.G2032R


3. Anti-proliferation assay

CBP73192 fig.png

Figure 4. Anti-proliferation assay of two reference compounds on the SLC34A2-ROS1 [G2032R]/BaF3 Stable Cell Line.



CD74-ROS1 G2032R BaF3

CD74-ROS1 [G2032R] BaF3

CD74-ROS1 L2086F BaF3

CD74-ROS1 [L2086F] BaF3

KRAS G12D&Y96C BaF3

KRAS [G12D&amp;Y96C] BaF3

會(huì)員登錄

×

請輸入賬號(hào)

請輸入密碼

=

請輸驗(yàn)證碼

收藏該商鋪

X
該信息已收藏!
標(biāo)簽:
保存成功

(空格分隔,最多3個(gè),單個(gè)標(biāo)簽最多10個(gè)字符)

常用:

提示

X
您的留言已提交成功!我們將在第一時(shí)間回復(fù)您~

以上信息由企業(yè)自行提供,信息內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由相關(guān)企業(yè)負(fù)責(zé),化工儀器網(wǎng)對此不承擔(dān)任何保證責(zé)任。

溫馨提示:為規(guī)避購買風(fēng)險(xiǎn),建議您在購買產(chǎn)品前務(wù)必確認(rèn)供應(yīng)商資質(zhì)及產(chǎn)品質(zhì)量。

撥打電話
在線留言
主站蜘蛛池模板: 册亨县| 香格里拉县| 南康市| 佛教| 新乡市| 潜山县| 将乐县| 湖口县| 灌阳县| 板桥市| 三原县| 遵化市| 措美县| 白银市| 巴中市| 南昌市| 和硕县| 通州区| 海口市| 怀柔区| 铁岭县| 沙洋县| 钟祥市| 印江| 大宁县| 肇庆市| 和政县| 安平县| 垦利县| 乐业县| 蕉岭县| 启东市| 清流县| 隆子县| 西丰县| 开化县| 睢宁县| 叶城县| 丹棱县| 达拉特旗| 景德镇市|